NASDAQ$BCYC
Bicycle Therapeutics plc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided corporate update.
Bicycle Therapeutics reported financial results for the third quarter ended September 30, 2021, highlighting progress in clinical trials for BT5528 and BT8009, advancement of BT7480 into the clinic, and expansion of the Genentech collaboration.
- Provided a clinical update for ongoing Phase 1 dose escalation trials in BT5528 and BT8009.
- Observed preliminary anti-tumor activity in both trials across two tumor types.
- BT7480, a Bicycle TICA™, recently entered the clinic.
- Expanded partnership with Genentech to include a new program.
Headline financials
Revenue & EPS history
Bicycle · Revenue · Quarterly
$4.33M
Forward guidance
Bicycle Therapeutics anticipates further advancements in its product candidates, including BT5528, BT8009 and BT7480, and the continued progression of clinical trials.
Tailwinds
- Anticipated advancement of its product candidates
- Advancement of Bicycle’s product candidate pipeline
- Initiation of enrollment in and progression of Bicycle’s and its collaboration partners’ clinical trials
- Availability and timing of data from clinical trials
- Potential to receive milestone payments and royalties under its license and collaboration agreement with Ionis
Headwinds
- Risks to site initiation, clinical trial commencement, patient enrollment and follow-up presented by the ongoing COVID-19 pandemic
- Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle’s product candidates by Bicycle or its collaboration partners
- Risk that Bicycle may not realize the intended benefits of its technology
- Availability and timing of results from preclinical studies and clinical trials
- Potential adverse effects arising from the testing or use of Bicycle’s product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+19.3%
Q4 2019
Best reaction
-10.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | +3.6% | -0.8% | |
| Q4 2025 | -4.2% | -13.9% | +1.8% | |
| Q3 2025 | +6.7% | -16.0% | -8.6% | |
| Q1 2025 | +6.1% | -13.6% | -4.0% | |
| Q4 2024 | -1.3% | -2.5% | -18.3% | |
| Q3 2024 | -5.5% | -2.2% | -15.1% | |
| Q2 2024 | -0.7% | +2.1% | -10.0% | |
| Q1 2024 | +1.6% | -4.6% | -8.3% | |
| Q4 2023 | +3.1% | +9.5% | +14.9% | |
| Q3 2023 | +1.2% | -0.7% | -2.3% | |
| Q2 2023 | +1.3% | -2.8% | -4.1% | |
| Q1 2023 | -0.4% | +2.5% | +15.7% | |
| Q4 2022 | -1.9% | -5.5% | -6.2% | |
| Q3 2022 | -3.2% | +0.8% | +29.6% | |
| Q2 2022 | +14.8% | +17.7% | +12.8% | |
| Q1 2022 | -10.8% | -22.6% | -33.6% | |
| Q4 2021 | -1.2% | -9.7% | -7.6% | |
| Q3 2021 | +0.7% | +2.5% | -6.8% | |
| Q2 2021 | +1.8% | +2.3% | +36.0% | |
| Q1 2021 | +1.9% | -1.3% | -5.5% | |
| Q4 2020 | +1.9% | +2.0% | +3.8% | |
| Q3 2020 | -1.5% | +3.1% | +5.2% | |
| Q2 2020 | -0.2% | +0.0% | +5.8% | |
| Q1 2020 | +0.7% | +6.6% | +23.2% | |
| Q4 2019 | +19.3% | +1.5% | -2.3% | |
| Q3 2019 | -4.2% | -7.7% | -4.8% | |
| Q2 2019 | +5.9% | +5.4% | -6.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro